ClinicalTrials.gg
CompletedNCT04465396Updated Oct 4, 2022Results posted

A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants

A Phase 1 interventional study of Teduglutide and Syringe Injection in Healthy Volunteers, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the bioavailability of teduglutide administered as a single subcutaneous (SC) fixed dose (depending upon participant weightband assignment) delivered by a syringe injection and the same fixed dose delivered by the pen injector in healthy participants.

Read the detailed description

This is a 2-period crossover study and consists of two cohorts. Cohort 1 consists of participant's with greater than or equal to (>=) 40.0 kilogram (kg) to lesser than or equal to (\<=) 75.0 kg of weight and Cohort 2 consists of participant's with greater than (>) 75.0 kg to \<= 120.0 kg of weight. Participants in each cohort will be randomized to 1 of 2 treatment sequences AB or BA. Randomization will be stratified by injection site (i.e., thigh, abdomen, and arm) within each cohort.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.

First submitted after Shire became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An understanding, ability, and willingness to fully comply with study procedures and restrictions.
  • Ability to voluntarily provide written, signed, and dated and assent as applicable to participate in the study.
  • Aged 18 - 45 inclusive at the time of consent. The date of signature of the informed consent is defined as the beginning of the screening period. This inclusion criterion will only be assessed at the first screening visit.
  • Male, or non-pregnant, non-lactating female who agrees to comply with any applicable requirements of the protocol or females of non-.
  • Considered "healthy" by the investigator. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a full physical examination including vital signs, 12-lead (ECG), hematology, coagulation (as appropriate), serum chemistry, and urinalysis.
  • (BMI) >= 18.0 and l\<=32.0 kilogram per square meter (kg/m\^2) at screening. Body weight for a participant in Cohort 1 will be >= 40.0 kg to \<= 75.0 kg, and body weight for a participant in Cohort 2 will be > 75.0 kg to \<= 120.0 kg, inclusive. This inclusion criterion will be assessed at the screening visit and confirmed at first check-in.

Exclusion criteria

Exclusion Criteria:

  • History of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or psychiatric disease, gall bladder removal, or current or recurrent disease that could affect the action, absorption, or disposition of the product, or clinical or laboratory assessments.
  • Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.
  • Positive PCR (polymerase chain reaction) test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), either with the absence or presence of the clinical symptoms of Coronavirus disease 2019 (COVID-19).
  • Known or suspected intolerance or to teduglutide, closely-related compounds, or any of the stated ingredients.
  • Significant illness, as judged by the investigator, within 2 weeks of the first dose of teduglutide.
  • Known history of alcohol or other substance abuse within the last year prior to screening.
  • Donation of blood or blood products (e.g. plasma or ) within 60 days prior to receiving the first dose of teduglutide.
  • Pregnant or lactating female.
  • Within 30 days prior to the first dose of teduglutide:

    1. Have used an investigational product (if elimination half-life is lesser than [\<] 6 days, otherwise 5 half-lives)
    2. Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's (or designee's) opinion, may impact this study
    3. Have had any substantial changes in eating habits, as assessed by the investigator (or designee)
  • Use of dipeptidyl peptidase 4 inhibitors within 30 days or 5 half-lives, whichever is greater, prior to administration of the first dose of teduglutide.
  • Confirmed systolic blood pressure > 140 millimeter of mercury (mmHg) or \< 90 mmHg, and diastolic blood pressure > 90 mmHg or \< 40 mmHg at screening.
  • Twelve-lead (ECG) demonstrating > 450 milliseconds (msec) at screening. If the QTcF exceeds the aforementioned limits, the ECG should be repeated 2 more times and the average of the 3 QTcF values should be used to determine the participants eligibility.
  • Positive screen for drugs of abuse or alcohol at screening and at each check-in.
  • Male participants who consume more than 21 units of alcohol per week or regularly consume more than 3 units per day. Female participants who consume more than 14 units of alcohol per week or regularly consume more than 2 units per day. (1 alcohol unit=150 milliliter [mL] of wine, or 360 mL of beer, or 45 mL of 45 percent [%] alcohol).
  • Positive (HIV), surface antigen (HBsAg), or virus (HCV) antibody screen at screening.
  • Use of tobacco in any form (e.g. smoking or chewing) or other nicotine-containing products in any form (e.g. gum, patch) based on participant self-reporting. Ex-users must report that they have stopped using tobacco for at least 3 months prior to receiving the first dose of teduglutide.
  • Routine consumption of more than 2 units of caffeine per day or participants who experience caffeine withdrawal headaches. One caffeine unit is contained in the following items: one 6 ounce (oz) (180 mL) cup of coffee, two 12 oz (360 mL) cans of cola, one 12 oz (360 mL) cup of tea, three 1 oz (85 gram [g]) chocolate bars.
  • Prior screen failure, randomization, participation, or enrollment in this study, or prior exposure to any Glucagon-like peptide 2 (GLP-2) analogs.
  • Presence of lesions, rashes, tattoos, and moles etc. on administration sites not allowing adequate conduct of injection site reaction and injection site injury assessment
  • Current use of any medication (including over-the-counter, herbal, or homeopathic preparations; with the exception of occasional use of ibuprofen [1.2 g per 24 hour period] or acetaminophen [2 g per 24 hour period]). Current use is defined as use within 14 days of the first dose of teduglutide and throughout the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)

    Teduglutide, 3 mg, subcutaneous (SC) injection using a syringe, once on Day 1 of Treatment Period 1 (Treatment A1), followed by same dose SC pen injector, once on Day 1 of Treatment Period 2 (Treatment B1). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants with \>=40.0 kg to \<=75.0 kg of weight were included in Cohort 1.

    Drug: Teduglutide · Device: Syringe Injection · Device: Pen injector

  • Experimental
    Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)

    Teduglutide, 3 mg, SC pen injector, once on Day 1 of Treatment Period 1 (Treatment B1), followed by same dose SC injection using a syringe, once on Day 1 of Treatment Period 2 (Treatment A1). A Washout Period of 7 days was maintained between the Treatment Periods 1 and 2. Participants with \>=40.0 kg to \<=75.0 kg of weight were included in Cohort 1.

    Drug: Teduglutide · Device: Syringe Injection · Device: Pen injector

  • Experimental
    Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)

    Teduglutide, 4 mg, SC injection using a syringe, once on Day 1 of Treatment Period 1 (Treatment A2), followed by same dose SC pen injector, once on Day 1 of Treatment Period 2 (Treatment B2). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants \>75.0 kg to \<=120.0 kg of weight were included in Cohort 2.

    Drug: Teduglutide · Device: Syringe Injection · Device: Pen injector

  • Experimental
    Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)

    Teduglutide, 4 mg, SC pen injector, once on Day 1 of Treatment Period 1 (Treatment B2), followed by same dose SC injection using a syringe, once on Day 1 of Treatment Period 2 (Treatment A2). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants \>75.0 kg to \<=120.0 kg of weight were included in Cohort 2.

    Drug: Teduglutide · Device: Syringe Injection · Device: Pen injector

Interventions

  • Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.

    Also known as: TAK-633

  • DeviceSyringe Injection

    Teduglutide was administered using syringe.

  • DevicePen injector

    Teduglutide was administered using pen injector.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2

  2. Maximum Observed Plasma Concentration (Cmax) of Teduglutide

    Cmax is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2

  3. Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2

Secondary outcomes

  1. Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide by Injection Site

    AUC0-last of teduglutide by injection site (i.e., thigh, abdomen, and arm) was assessed and reported.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2

  2. Maximum Observed Plasma Concentration (Cmax) of Teduglutide by Injection Site

    Cmax of teduglutide by injection site (i.e., thigh, abdomen, and arm) was assessed and reported.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2

  3. Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide by Injection Site

    AUC0-infinity of teduglutide by injection site (i.e., thigh, abdomen, and arm) was assessed and reported.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2

  4. Time of First Occurrence of Maximum Observed Plasma Concentration (Cmax) [Tmax] of Teduglutide

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2

  5. Terminal Disposition Phase Rate Constant (Lambda z) of Teduglutide

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2

  6. Terminal Disposition Phase Half-Life (t1/2z) of Teduglutide

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2

  7. Apparent Total Body Clearance (CL/F) of Teduglutide

    CL/F for extravascular administration divided by the fraction of dose absorbed of teduglutide was assessed and reported.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2

  8. Apparent Volume of Distribution (Vz/F) of Teduglutide

    Vz/F associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed of teduglutide was assessed and reported.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2

  9. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE was defined as an AE that started or worsened at the time of or after study drug administration. Number of participants with TEAEs included injection site reactions and injection site injury assessments.

    Time frame: From the start of study drug administration up to follow-up (up to 42 days)

  10. Number of Participants With Clinically Significant Change in Vital Signs

    Vital signs included body temperature, respiratory rate, blood pressure, and heart rate.

    Time frame: From the start of study drug administration up to follow-up (up to 42 days)

  11. Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

    Clinical laboratory assessments included hematology, serum chemistry, coagulation, and urinalysis. Changes in laboratory values may be considered as AE if they were judged to be clinically significant.

    Time frame: From the start of study drug administration up to follow-up (up to 42 days)

  12. Number of Participants With Clinically Significant Changes in Physical Examinations

    Physical examination included examination of respiratory, cardiovascular, and gastrointestinal system.

    Time frame: From the start of study drug administration up to follow-up (up to 42 days)

  13. Number of Participants With Device Malfunction

    Number of participants with device malfunction was assessed and reported. The site staff reported any malfunctions whilst using the device.

    Time frame: Day 1

07

Results

Posted Oct 4, 2022

Participant flow

Participants took part in the study at 1 investigative site in the United States from 13 January 2021 to 20 August 2021.

Treatment Period 1 (Day 1)
Participant flow — Treatment Period 1 (Day 1)
MilestoneCohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)
Started16161616
Completed16161616
Not completed0000
Washout Period (7 Days)
Participant flow — Washout Period (7 Days)
MilestoneCohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)
Started16161616
Completed16161616
Not completed0000
Treatment Period 2 (Day 1)
Participant flow — Treatment Period 2 (Day 1)
MilestoneCohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)
Started16161616
Completed16151516
Not completed0110
Withdrew: Lost to follow-up0110

Outcome measures

PrimaryArea Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide
Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Reported as:
Geometric mean · ng*hour/mL
Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide
ng*hour/mLCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide217.2 ± 21.0237.2 ± 22.1221.9 ± 21.2253.0 ± 21.4
Statistical analysis
  • Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) vs Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) · Geometric mean ratio: 109.22 · 90% CI 104.83 to 113.80The analysis was performed using Proc Mixed in statistical software suite (SAS), with treatment, sequence, period, and participant within sequence as fixed effects.
  • Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) vs Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) · Geometric mean ratio: 113.99 · 90% CI 108.32 to 119.95The analysis was performed using Proc Mixed in SAS, with treatment, sequence, period, and participant within sequence as fixed effects.
PrimaryMaximum Observed Plasma Concentration (Cmax) of Teduglutide

Cmax is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Teduglutide
ng/mLCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Maximum Observed Plasma Concentration (Cmax) of Teduglutide33.90 ± 37.733.31 ± 37.631.99 ± 34.829.58 ± 32.6
Statistical analysis
  • Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) vs Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) · Geometric mean ratio: 98.27 · 90% CI 88.50 to 109.11The analysis was performed using Proc Mixed in SAS, with treatment, sequence, period, and participant within sequence as fixed effects.
  • Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) vs Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) · Geometric mean ratio: 92.48 · 90% CI 83.80 to 102.05The analysis was performed using Proc Mixed in SAS, with treatment, sequence, period, and participant within sequence as fixed effects.
PrimaryArea Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide
Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide
ng*hr/mLCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide227.6 ± 21.1249.2 ± 20.8227.1 ± 20.8268.2 ± 22.2
Statistical analysis
  • Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection) vs Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector) · Geometric mean ratio: 109.44 · 90% CI 105.51 to 113.51The analysis was performed using Proc Mixed in SAS, with treatment, sequence, period, and participant within sequence as fixed effects.
  • Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection) vs Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector) · Geometric mean ratio: 118.40 · 90% CI 112.31 to 124.83The analysis was performed using Proc Mixed in SAS, with treatment, sequence, period, and participant within sequence as fixed effects.
SecondaryArea Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide by Injection Site

AUC0-last of teduglutide by injection site (i.e., thigh, abdomen, and arm) was assessed and reported.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide by Injection Site
ng*hr/mLCohort 1 (Teduglutide 3 mg): Syringe Injection in AbdomenCohort 1 (Teduglutide 3 mg): Syringe Injection in ArmCohort 1 (Teduglutide 3 mg): Syringe Injection in ThighCohort 1 (Teduglutide 3 mg): Pen Injector in AbdomenCohort 1 (Teduglutide 3 mg): Pen Injector in ArmCohort 1 (Teduglutide 3 mg): Pen Injector in ThighCohort 2 (Teduglutide 4 mg): Syringe Injection in AbdomenCohort 2 (Teduglutide 4 mg): Syringe Injection in ArmCohort 2 (Teduglutide 4 mg): Syringe Injection in ThighCohort 2 (Teduglutide 4 mg): Pen Injector in AbdomenCohort 2 (Teduglutide 4 mg): Pen Injector in ArmCohort 2 (Teduglutide 4 mg): Pen Injector in Thigh
Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-last) of Teduglutide by Injection Site241.2 ± 14.0205.8 ± 29.1202.2 ± 14.4277.6 ± 9.1216.6 ± 27.8215.2 ± 16.7219.6 ± 17.2222.6 ± 27.9224.1 ± 20.3239.5 ± 19.0277.3 ± 23.3246.4 ± 21.3
SecondaryMaximum Observed Plasma Concentration (Cmax) of Teduglutide by Injection Site

Cmax of teduglutide by injection site (i.e., thigh, abdomen, and arm) was assessed and reported.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Teduglutide by Injection Site
ng/mLCohort 1 (Teduglutide 3 mg): Syringe Injection in AbdomenCohort 1 (Teduglutide 3 mg): Syringe Injection in ArmCohort 1 (Teduglutide 3 mg): Syringe Injection in ThighCohort 1 (Teduglutide 3 mg): Pen Injector in AbdomenCohort 1 (Teduglutide 3 mg): Pen Injector in ArmCohort 1 (Teduglutide 3 mg): Pen Injector in ThighCohort 2 (Teduglutide 4 mg): Syringe Injection in AbdomenCohort 2 (Teduglutide 4 mg): Syringe Injection in ArmCohort 2 (Teduglutide 4 mg): Syringe Injection in ThighCohort 2 (Teduglutide 4 mg): Pen Injector in AbdomenCohort 2 (Teduglutide 4 mg): Pen Injector in ArmCohort 2 (Teduglutide 4 mg): Pen Injector in Thigh
Maximum Observed Plasma Concentration (Cmax) of Teduglutide by Injection Site40.84 ± 29.731.66 ± 41.629.02 ± 35.243.65 ± 20.728.73 ± 43.927.91 ± 27.326.86 ± 25.938.28 ± 43.832.97 ± 25.028.14 ± 30.432.33 ± 33.828.73 ± 35.5
SecondaryArea Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide by Injection Site

AUC0-infinity of teduglutide by injection site (i.e., thigh, abdomen, and arm) was assessed and reported.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide by Injection Site
ng*hr/mLCohort 1 (Teduglutide 3 mg): Syringe Injection in AbdomenCohort 1 (Teduglutide 3 mg): Syringe Injection in ArmCohort 1 (Teduglutide 3 mg): Syringe Injection in ThighCohort 1 (Teduglutide 3 mg): Pen Injector in AbdomenCohort 1 (Teduglutide 3 mg): Pen Injector in ArmCohort 1 (Teduglutide 3 mg): Pen Injector in ThighCohort 2 (Teduglutide 4 mg): Syringe Injection in AbdomenCohort 2 (Teduglutide 4 mg): Syringe Injection in ArmCohort 2 (Teduglutide 4 mg): Syringe Injection in ThighCohort 2 (Teduglutide 4 mg): Pen Injector in AbdomenCohort 2 (Teduglutide 4 mg): Pen Injector in ArmCohort 2 (Teduglutide 4 mg): Pen Injector in Thigh
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide by Injection Site246.6 ± 13.2213.0 ± 29.5218.6 ± 18.7282.3 ± 9.1229.6 ± 26.8229.2 ± 18.6224.7 ± 17.6228.2 ± 27.1228.7 ± 20.0247.0 ± 19.7296.8 ± 24.4268.1 ± 20.9
SecondaryTime of First Occurrence of Maximum Observed Plasma Concentration (Cmax) [Tmax] of Teduglutide
Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Reported as:
Median · hour
Time of First Occurrence of Maximum Observed Plasma Concentration (Cmax) [Tmax] of Teduglutide
hourCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Time of First Occurrence of Maximum Observed Plasma Concentration (Cmax) [Tmax] of Teduglutide4.002 (2.00 to 8.06)4.001 (0.50 to 8.05)4.999 (2.01 to 8.04)4.507 (2.00 to 12.00)
SecondaryTerminal Disposition Phase Rate Constant (Lambda z) of Teduglutide
Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Reported as:
Geometric mean · 1/hr
Terminal Disposition Phase Rate Constant (Lambda z) of Teduglutide
1/hrCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Terminal Disposition Phase Rate Constant (Lambda z) of Teduglutide0.4055 ± 51.20.4191 ± 41.00.3971 ± 41.80.3236 ± 48.1
SecondaryTerminal Disposition Phase Half-Life (t1/2z) of Teduglutide
Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Reported as:
Mean · hour
Terminal Disposition Phase Half-Life (t1/2z) of Teduglutide
hourCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Terminal Disposition Phase Half-Life (t1/2z) of Teduglutide1.930 ± 1.10701.797 ± 0.83411.903 ± 0.91072.385 ± 1.2292
SecondaryApparent Total Body Clearance (CL/F) of Teduglutide

CL/F for extravascular administration divided by the fraction of dose absorbed of teduglutide was assessed and reported.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Reported as:
Mean · Liter(L)/hr
Apparent Total Body Clearance (CL/F) of Teduglutide
Liter(L)/hrCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Apparent Total Body Clearance (CL/F) of Teduglutide13.48 ± 3.206012.31 ± 2.933217.97 ± 3.573715.27 ± 3.5042
SecondaryApparent Volume of Distribution (Vz/F) of Teduglutide

Vz/F associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed of teduglutide was assessed and reported.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours post-dose of Treatment Period 1 and Treatment Period 2
Reported as:
Mean · L
Apparent Volume of Distribution (Vz/F) of Teduglutide
LCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Apparent Volume of Distribution (Vz/F) of Teduglutide36.85 ± 18.83731.86 ± 15.38249.84 ± 27.39451.01 ± 23.867
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE was defined as an AE that started or worsened at the time of or after study drug administration. Number of participants with TEAEs included injection site reactions and injection site injury assessments.

Time frame:
From the start of study drug administration up to follow-up (up to 42 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)131095
SecondaryNumber of Participants With Clinically Significant Change in Vital Signs

Vital signs included body temperature, respiratory rate, blood pressure, and heart rate.

Time frame:
From the start of study drug administration up to follow-up (up to 42 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change in Vital Signs
ParticipantsCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Number of Participants With Clinically Significant Change in Vital Signs0000
SecondaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

Clinical laboratory assessments included hematology, serum chemistry, coagulation, and urinalysis. Changes in laboratory values may be considered as AE if they were judged to be clinically significant.

Time frame:
From the start of study drug administration up to follow-up (up to 42 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
ParticipantsCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments0000
SecondaryNumber of Participants With Clinically Significant Changes in Physical Examinations

Physical examination included examination of respiratory, cardiovascular, and gastrointestinal system.

Time frame:
From the start of study drug administration up to follow-up (up to 42 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Physical Examinations
ParticipantsCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection))Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Number of Participants With Clinically Significant Changes in Physical Examinations0000
SecondaryNumber of Participants With Device Malfunction

Number of participants with device malfunction was assessed and reported. The site staff reported any malfunctions whilst using the device.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants With Device Malfunction
ParticipantsCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
Number of Participants With Device Malfunction0000

Adverse events

Collected over From the start of study drug administration up to follow-up (up to 42 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)0/32 (0%)0/32 (0%)13/32 (40.6%)
Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)0/32 (0%)0/32 (0%)10/32 (31.3%)
Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)0/32 (0%)0/32 (0%)9/32 (28.1%)
Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)0/32 (0%)0/32 (0%)1/32 (3.1%)
Most frequent other events
Most frequent other events
EventCohort 1 (Teduglutide 3 mg): Treatment A1 (Syringe Injection)Cohort 1 (Teduglutide 3 mg): Treatment B1 (Pen Injector)Cohort 2 (Teduglutide 4 mg): Treatment A2 (Syringe Injection)Cohort 2 (Teduglutide 4 mg): Treatment B2 (Pen Injector)
NauseaGastrointestinal disorders1/324/320/320/32
Abdominal painGastrointestinal disorders0/323/320/320/32
Injection site painGeneral disorders2/321/323/321/32
DizzinessNervous system disorders2/323/320/320/32
Vision blurredEye disorders0/322/320/320/32
Abdominal distensionGastrointestinal disorders2/322/322/320/32
VomitingGastrointestinal disorders2/320/320/320/32
Injection site erythemaGeneral disorders2/321/322/320/32
Vessel puncture site painGeneral disorders1/322/320/320/32
HeadacheNervous system disorders2/320/322/320/32

Baseline characteristics

Safety Set included all participants who received at least one dose of the study drug.

Age, Continuous
Age, Continuous(years)Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)Total
Mean31.8 (20 to 41)32.4 (20 to 45)32.5 (18 to 39)35.9 (23 to 45)33.2 (18 to 45)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)Total
Female992121
Male77141543
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)Total
Hispanic or Latino10149942
Not Hispanic or Latino627722
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American224311
White1214101349
More than one race00101
Unknown or Not Reported20103
Region of Enrollment
Region of Enrollment(Participants)Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)Total
United States1616161664
Height
Height(cm)Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)Total
Mean163.19 (151.0 to 175.0)164.06 (151.0 to 177.0)173.81 (165.0 to 189.0)175.38 (163.0 to 187.0)169.11 (151 to 189)
Weight
Weight(kg)Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)Total
Mean64.38 (55.4 to 73.5)66.51 (55.8 to 73.4)86.39 (74.9 to 108.8)84.68 (75.3 to 106.8)75.49 (55.4 to 108.8)
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)Total
Mean24.271 (19.31 to 30.72)24.891 (20.12 to 30.25)28.558 (23.98 to 31.81)27.530 (22.99 to 31.41)26.313 (19.31 to 31.81)
08

Study locations

1 site
  • Celerion
    Phoenix, Arizona 85283, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Aug 2021, 7 months.

Results were first posted in Oct 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2020
First posted
Jul 10, 2020
StartActual
Jan 13, 2021
Primary completionActual
Aug 20, 2021
CompletionActual
Aug 20, 2021
Results first posted
Oct 4, 2022
Last update
Oct 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04465396
Lead sponsor
Shire
Collaborators
Takeda Development Center Americas, Inc.
Responsible party
Sponsor
First posted
Jul 10, 2020
Start date
Jan 13, 2021
Primary completion
Aug 20, 2021
Completion
Aug 20, 2021
Results posted
Oct 4, 2022
Last update
Oct 4, 2022

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion